Mirae Asset Global Investments Co. Ltd. Sells 38,748 Shares of Solventum Corporation $SOLV

Key Points

• Mirae Asset Global Investments Co. Ltd. sold 38,748 shares of Solventum Corporation, reducing its stake by 68.4%, leaving it with 17,869 shares valued at approximately $1.36 million.
• Several institutional investors, including Independent Franchise Partners and Boston Partners, significantly increased their stakes in Solventum during the first quarter, showcasing growing interest in the company.
• Solventum Corporation reported a quarterly earnings per share (EPS) of $1.69, exceeding the consensus estimate and demonstrating a 3.8% revenue increase year-over-year, with projections for FY 2025 EPS ranging between 5.800 and 5.950.

Mirae Asset Global Investments Co. Ltd. lessened its position in Solventum Corporation (NYSE:SOLV - Free Report) by 68.4% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 17,869 shares of the company's stock after selling 38,748 shares during the period. Mirae Asset Global Investments Co. Ltd.'s holdings in Solventum were worth $1,355,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of the company. Independent Franchise Partners LLP increased its stake in Solventum by 263.1% in the first quarter. Independent Franchise Partners LLP now owns 5,820,724 shares of the company's stock valued at $442,608,000 after purchasing an additional 4,217,570 shares in the last quarter. Davis Selected Advisers increased its stake in Solventum by 0.8% in the first quarter. Davis Selected Advisers now owns 5,288,138 shares of the company's stock valued at $402,110,000 after purchasing an additional 41,524 shares in the last quarter. Boston Partners increased its stake in Solventum by 101.3% in the first quarter. Boston Partners now owns 3,361,973 shares of the company's stock valued at $255,554,000 after purchasing an additional 1,691,565 shares in the last quarter. Northern Trust Corp increased its stake in Solventum by 3.3% in the first quarter. Northern Trust Corp now owns 1,807,674 shares of the company's stock valued at $137,456,000 after purchasing an additional 58,373 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its stake in Solventum by 2.2% in the first quarter. Charles Schwab Investment Management Inc. now owns 1,173,960 shares of the company's stock valued at $89,268,000 after purchasing an additional 24,762 shares in the last quarter.

Solventum Stock Performance

NYSE SOLV opened at $71.73 on Friday. The company has a current ratio of 1.22, a quick ratio of 0.86 and a debt-to-equity ratio of 2.14. The firm's fifty day moving average price is $72.77 and its two-hundred day moving average price is $72.14. Solventum Corporation has a 1 year low of $60.70 and a 1 year high of $85.92. The firm has a market capitalization of $12.44 billion, a P/E ratio of 33.21, a price-to-earnings-growth ratio of 2.95 and a beta of 0.50.

Solventum (NYSE:SOLV - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported $1.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.45 by $0.24. Solventum had a net margin of 4.52% and a return on equity of 29.93%. The firm had revenue of $2.16 billion for the quarter, compared to analyst estimates of $2.12 billion. During the same period in the prior year, the firm posted $1.56 earnings per share. The company's quarterly revenue was up 3.8% compared to the same quarter last year. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. As a group, research analysts anticipate that Solventum Corporation will post 6.58 EPS for the current year.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Wall Street Zen cut shares of Solventum from a "strong-buy" rating to a "buy" rating in a report on Tuesday, September 9th. Piper Sandler reiterated an "overweight" rating and issued a $94.00 price target (up previously from $87.00) on shares of Solventum in a report on Friday, August 8th. Morgan Stanley upgraded shares of Solventum from an "equal weight" rating to an "overweight" rating and upped their price target for the company from $80.00 to $103.00 in a report on Tuesday, July 15th. UBS Group assumed coverage on shares of Solventum in a report on Wednesday, October 1st. They issued a "neutral" rating and a $77.00 price target for the company. Finally, Zacks Research upgraded shares of Solventum from a "hold" rating to a "strong-buy" rating in a report on Monday, September 15th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Solventum currently has an average rating of "Hold" and a consensus price target of $84.89.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.

Want to see what other hedge funds are holding SOLV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Solventum Corporation (NYSE:SOLV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.